PRKN and cancer: How this is orchestrated remains to be elucidated, but reintroduction of PRKN in different cancer types is sufficient to inhibit several intrinsic tumor traits, such as mitotic transitions (32), metabolic reprogramming through the pentose phosphate pathway (30), and phosphoglycerate dehydrogenase (33), as well as heightened cell motility and invasion cell motility and invasion (34).